Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.

Eli Lilly shares have surged ~225% over the past three years amid strong demand for its GLP-1 drugs, leaving the stock trading at a rich ~49x P/E and suggesting limited upside for new buyers. Novo Nordisk — first to market with GLP-1 drugs and the initial GLP-1 pill — is seeing faster-than-expected pill uptake but has fallen ~66% from 2024 highs and cautioned that 2026 earnings will be weak despite long-term volume growth potential. Medtronic plans a 2026 spinoff of its lower-margin diabetes unit, which management expects to be immediately accretive and allow its higher-margin cardiovascular, neuroscience and medical-surgical franchises to drive faster growth; the stock remains >20% below 2021 peaks.

Analysis

Market structure: GLP-1 winners are the drug makers with scalable oral formulations and manufacturing capacity — Novo Nordisk (NVO) captures volume upside from its first-to-market pill while Eli Lilly (LLY) retains pricing power in injectables and brand momentum. Medtronic (MDT) is a different bet: splitting off lower-margin diabetes ops should boost reported margins and re-rate the premium businesses (cardio/neuro) if execution is clean, implying 15–30% re-rating potential over 12–24 months. Demand signal: faster-than-expected pill uptake implies durable secular demand, pressuring payors and likely compressing prices over a multi-year window as scale drives negotiating leverage.

Risk assessment: tail risks include rapid regulatory intervention (class-wide safety reviews or stricter labeling) or payer-driven access limits that could cut market volumes 20–50% in a stress scenario; litigation from off-label use is a 1–3 year hazard. Time horizons vary: price moves in days around earnings/guidance, volume/pricing dynamics over 6–18 months, structural market-share shifts over 2–5 years. Hidden dependencies include specialty-pharmacy bottlenecks, raw-material capacity for GLP-1 synthesis, and Medtronic spin-off tax/financing structure risks that could dilute near-term returns.

Trade implications: establish directional exposure to NVO and MDT while avoiding full-price chase into LLY: consider a 3% portfolio long in NVO via Jan-2028 LEAPS calls (ATM) to capture 12–36 month volume ramp, and a 2–3% long in MDT ahead of the 2026 spin with a 12–18 month target +20–30%. Hedge LLY exposure by selling 3–6 month covered calls or buying 6-month puts (strike ~10–15% OTM) to protect against mean reversion from a high 49x P/E. Pair trade: long NVO (3%) / short LLY (1.5%) sized ~2:1 to reflect valuation gap and volatility skew; tighten stops to 20% or rebalance on catalyst events.

Contrarian angles: consensus underestimates the speed and stickiness of GLP-1 adoption in primary care — if payors concede broader access, volumes could surprise to the upside and benefit NVO materially, making the -66% drawdown an overreaction. Conversely, the market may be underpricing payer/regulatory clampdown risk that would hurt all GLP-1 names and benefit defensive MedTech; MDT upside is conditional on clean spin execution. Historical parallel: insulin pricing cycles show price/regulatory whipsaws — prepare for binary outcomes and size positions to survive 30–50% interim swings.

Key Decisions for Investors

• Initiate a 3% portfolio long position in Novo Nordisk (NVO) using Jan‑2028 LEAPS calls (ATM) or equivalent equity exposure; target 30–50% absolute upside over 12–36 months as pill volumes scale. Trim or stop‑loss if shares decline another 20% or if payer restrictions announced within 90 days.
• Establish a 2–3% long in Medtronic (MDT) equity ahead of the 2026 diabetes spinoff, target 20–30% upside within 12–18 months post-spin; reduce if spin structure increases net leverage or if guidance shows margin drag >200bps versus current consensus.
• Implement a pair trade: long NVO (3%) / short Eli Lilly (LLY) (1.5%) to express relative value; rebalance on quarterly earnings and exit or flip if relative performance reverses by 15% or after major payer rulings. Use size asymmetry (2:1) to reflect valuation and volatility differences.
• Protect existing LLY exposure by selling 3–6 month covered calls (collect premium) or buying 6‑month puts ~10–15% OTM if no ability to reduce core position; reduce exposure if growth guidance misses and P/E compresses below 40.
• Monitor 4 catalysts for active management: NVO pill uptake metrics and prescription data weekly for 3 months, US payer formulary decisions within 30–90 days, MDT spin-off filings and leverage disclosures when released (target Q4 2025–Q1 2026), and any FDA safety communications — act within 7 trading days of material announcements.